Medicare beneficiaries with a body-mass index of 27 or higher and a history of heart attack, stroke, symptomatic peripheral artery disease, or prediabetes will gain access to GLP-1 medications for a $50 copay starting July 1, 2026. The short-term demonstration, set to run through December 31, 2027, represents a workaround to longstanding federal law that bars Medicare Part D from covering drugs used for weight loss. The program’s narrow eligibility criteria and fixed copay raise a direct question: can 18 months of low-cost access produce real reductions in cardiovascular hospitalizations among older adults?
Why a $50 GLP-1 copay changes the calculus for Medicare enrollees
Federal statute has blocked Medicare Part D from covering weight-loss drugs for decades. The Social Security Act permits exclusion of agents used for anorexia, weight loss, or weight gain, and Part D’s drug definition incorporates those same exclusion categories. That legal barrier forced CMS to build the new program entirely outside the Part D payment flow. The $50 copay does not count toward a beneficiary’s true out-of-pocket costs, and no Low-Income Subsidy applies, according to the CMS bridge guidance.
The practical effect for qualifying enrollees is significant. Commercial plans that cover GLP-1 drugs like semaglutide often charge hundreds of dollars per month in cost-sharing, creating well-documented adherence problems. A flat $50 monthly copay removes the price volatility that drives patients to stop treatment, particularly when list prices for GLP-1 therapies remain high. For older adults on fixed incomes, the predictability of a set copay can be as important as the lower dollar amount itself, allowing beneficiaries and caregivers to budget around a stable monthly expense rather than fluctuating coinsurance tied to a drug’s list price.
If adherence holds at higher rates than commercial benchmarks, the 18-month window could generate enough cardiovascular outcome data to justify a longer-term coverage pathway, though CMS has not published enrollment projections or post-2027 extension plans. Because the demonstration is carved out from the standard Part D benefit, plans will not be able to apply usual utilization management tools such as step therapy or tiered cost-sharing; instead, the main gatekeepers will be clinical eligibility checks and pharmacy participation rules. That design places more weight on prescribers’ judgments about which patients are likely to benefit and remain on therapy long enough to affect cardiovascular risk.
SELECT trial data and the FDA approval anchoring eligibility
The clinical foundation for the program traces to the SELECT trial, registered as NCT03574597, which enrolled 17,604 patients with BMI of 27 or higher and preexisting cardiovascular disease but without diabetes. Semaglutide at 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20 percent, with a hazard ratio of 0.80, as published in a peer-reviewed analysis. Participants received standard-of-care treatment plus lifestyle counseling alongside the drug, reflecting real-world management of high-risk patients rather than an idealized trial population.
That evidence led the FDA to approve Wegovy on March 8, 2024 specifically to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. In its announcement, the agency framed semaglutide as the first therapy explicitly authorized to lower serious heart risks in this population, underscoring the shift from viewing GLP-1s solely as weight-loss agents to recognizing their cardiometabolic benefits, as described in the FDA press release.
The Medicare demonstration mirrors the trial’s inclusion criteria closely. CMS requires a BMI of 27 or above plus at least one qualifying condition: prior heart attack, prior stroke, symptomatic peripheral artery disease, or prediabetes, according to the agency’s program materials. By tying eligibility to documented cardiovascular disease or a clear metabolic warning sign, the initiative narrows its focus to beneficiaries whose absolute risk-and therefore potential absolute benefit-is highest. That alignment with SELECT’s design is critical if CMS hopes to replicate the trial’s relative risk reductions in a broader, older, and more clinically complex Medicare population.
Operational constraints and unanswered questions
Even with generous clinical evidence, the demonstration’s impact will depend on execution. Pharmacies must opt in and follow specific billing and documentation protocols distinct from standard Part D claims. CMS has outlined these expectations in its pharmacy information, emphasizing correct use of new identifiers so that GLP-1 fills are tracked separately from regular prescription benefits. Any confusion at the counter-about eligibility, copays, or claim submission-could slow uptake and undermine the program’s ability to generate timely data.
Prescribers, meanwhile, will need to navigate patient selection, prior documentation of qualifying events, and counseling around side effects that may be more challenging in frail or multimorbid seniors. Gastrointestinal intolerance, dehydration, and potential interactions with other chronic medications could lead to discontinuation, diluting the real-world effect size compared with SELECT. Yet if a substantial share of eligible beneficiaries can sustain treatment through the 18-month window, CMS will gain a rare, quasi-experimental view of how GLP-1–driven risk reduction plays out in fee-for-service Medicare.
The central policy question is whether a time-limited, off-Part-D bridge can demonstrate enough avoided heart attacks, strokes, and hospitalizations to justify a more permanent financing solution. Because the $50 copay is set administratively rather than tied to list prices or rebates, CMS will also be able to observe how a simple, predictable price point affects adherence compared with traditional benefit designs. By the end of 2027, the agency will face a choice: let the bridge expire, extend it, or push for statutory change that would allow cardiometabolic indications for GLP-1s to be integrated into Medicare’s core drug benefit. The demonstration’s outcomes-not just in clinical terms but in budget impact and beneficiary experience-will shape that decision.
